Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00106821 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 166
- Enrollment target
NCT00106821 is a Phase 4 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 166 participants.
The verdict
NCT00106821, a Phase 4 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 166 participants
- Enrollment target
Study Summary
The purpose of this study is to look at the benefits of tiotropium, an approved drug for the treatment of bronchospasm associated with COPD (chronic obstructive pulmonary disease), in a population of patients with COPD who are of African American descent.
Interventions
- DRUG Tiotropium Bromide Inhalation Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2004-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00106821
The ClinicalTrials.gov registry entry for NCT00106821 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tiotropium Bromide Inhalation Powder is the first listed.
NCT00106821 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00106821 about?
NCT00106821 is a clinical study titled "Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease". The purpose of this study is to look at the benefits of tiotropium, an approved drug for the treatment of bronchospasm associated with COPD (chronic obstructive pulmonary disease), in a population of patients with COPD who are of African American descent.
What is the current status of trial NCT00106821?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 166 participants. The study started on 2004-06.
What interventions are being tested in trial NCT00106821?
The interventions under investigation include: Tiotropium Bromide Inhalation Powder (DRUG).
Who is sponsoring clinical trial NCT00106821?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.